Agios Pharmaceuticals AGIO
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 48th percentile, 5-year average -3.4x
Above its usual level · 79th percentile, 5-year average 1.7x
#3005 of 5330 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 10th percentile, 5-year average 136.6x
#4613 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 1.93 | – | 1.66 | 79% (pricier than usual) | #3005 of 5330 (1 = cheapest) |
| PE | -5.01 | -8.27 | -3.38 | 48% (cheaper than usual) | – |
| PS | 13.41 | 6.18 | 136.55 | 10% (cheaper than usual) | #4613 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on AGIO.
Sign in to join the discussion.